We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

FDA Tells Cedax Maker To Fix Deceptive Marketing

Law360 (November 25, 2008, 12:00 AM EST) -- The marketing for Shionogi & Co. Ltd.’s antibiotic Cedax misleads the public by downplaying the drug’s risks and overstretching efficacy claims, the U.S. Food and Drug Administration said in a warning letter to the company on Nov. 14.

The FDA sent a letter ordering Shionogi USA Inc. CEO Sapan A. Shah to update the company's promotional materials to provide more accurate drug claims.

“These violations are concerning from a public health perspective because they suggest that the product is both safer and effective in a broader...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.